Answer
Burosumab has an approximate serum half-life of 16–19 days in typical adult (70 kg) and paediatric (30 kg) patients with X-linked hypophosphataemia.
Sources for this answer
- Crysvita solution for subcutaneous injectionKyowa Kirin Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 13Document updated
Sources checked